Shahrukh Hashmi

Prior to joining MBZUAI, Professor Hashmi started the Mayo Clinic’s first BMT survivorship program. He has served as PI or Co-PI on many industry-sponsored and NIH-sponsored trials.

Professor Hashmi chairs many national or international professional committees/groups including being the chair of the Worldwide Network for Blood and Marrow Transplant’s Nuclear Accident committee (Geneva, Switzerland), founding chair of American Society for Blood and Marrow Transplant Society’s Survivorship SIG (Chicago, Illinois), and co-chair of the Center for International Blood and Marrow Transplant Registry’s (CIBMTR) Health Services Committee (Milwaukee, Wisconsin). He is currently the chair of the Department of Hematology/Oncology at the SSMC, Abu Dhabi, UAE; and the chair of SEHA Oncology Council.

• 4BMT Fellowship - Blood and Marrow Transplant Program at James P. Wilmot Cancer Center, University of Rochester Medical Center, USA
• Fellow - Hematology/Oncology, Strong Memorial Hospital, University of Rochester Medical Center.
• Resident - Combined Preventive/Internal Medicine Program at Griffin Hospital, USA
• Master’s - Public Health; Division of Chronic Disease Epidemiology, Yale School of Public Health.
• MB BS - Medical Education - MBBS, Baqai Medical University, Undergraduate Studies.
• Fellow of Science (undergraduate) , DHA College for Men, Pakistan.

• Co-chair, Global Emergencies/Nuclear Accident Committee, Worldwide Network for Blood & Marrow Transplantation, 2020.
• Associate editor, Bone Marrow Transplantation, 2020.
• Editorial board member, Hematology/Oncology and Stem Cell Therapy, 2020.
• Editorial board member, Biology of Blood and Marrow Transplantation, 2019.
• Member, Steering Committee, Committee on Practice Guidelines, American Society for Transplantation and Cellular Therapy, 2019.
• Member, Nuclear Accident Committee, European Society for Blood and Marrow Transplantation, 2019.
• Co-Chair, Health Services and International Studies Working Committee, Center for International Blood & Marrow Transplant Research (CIBMTR), 2018.
• Member at Large, Advisory Committee (Non North America), CIBMTR, 2018.
• Chair, Survivorship Special Interest Group, American Society for Blood and Marrow Transplantation, 2016.
• Member, founding and steering committee, NIH BMT Late Effects Initiative, 2015.
• Member, Education Committee, PEAG, National Marrow Donor Program, 2014.
• Director, Long-Term Follow-Up Clinic for Blood and Marrow Transplant Survivors, Mayo Clinic, 2012.

Hashmi has authored more than 200 articles in peer-reviewed journals, including in JAMA, Lancet, and in NEJM.

• Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study
• JN Justice, AM Nambiar, T Tchkonia, NK LeBrasseur, R Pascual, et al. EBioMedicine 40, 554-563, 2019.
• Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. LTJ Hickson, LGPL Prata, SA Bobart, TK Evans, N Giorgadze, SK Hashmi, et al. EBioMedicine 47, 446-456, 2019.
• Survival after mesenchymal stromal cell therapy steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. S Hashmi, M Ahmed, MH Murad, MR Litzow, RH Adams, LM Ball, et al. The Lancet Haematology 3 (1), e45-e52, 2016.
• Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. L Muffly, MC Pasquini, M Martens, R Brazauskas, X Zhu, K Adekola, et al. Blood, The Journal of the American Society of Hematology 130 (9), 1156-1164, 2017.
• Lessons learned from large-scale, first-tier clinical exome sequencing in a highly consanguineous population. D Monies, M Abouelhoda, M Assoum, N Moghrabi, R Rafiullah, et al. The American Journal of Human Genetics 104 (6), 1182-1201, 2019.